The biopharma world is here
Endpoints’ industry-leading content draws a quality audience and high levels of engagement. Let’s connect your message with these top biopharma players using data-informed advertising to achieve your goals.
Endpoints’ industry-leading content draws a quality audience and high levels of engagement. Let’s connect your message with these top biopharma players using data-informed advertising to achieve your goals.
Endpoints News was founded in 2016 by John Carroll and Arsalan Arif to deliver the best news product in biopharma and become an essential read for industry leaders across the globe. Thanks to an ambitious team of journalists across the US, Europe and Asia and support from advertising partners, we're now read by thousands of innovative biotechs and every top 50 pharmaceutical company in the world. As a member of the Financial Times family, we're backed by the most respected global brand in business journalism and committed to providing advertisers with innovative ways to engage our growing audience of biopharma and healthcare executives across the globe.
Deliver your unique point of view in the clear, concise style readers expect from Endpoints News with one of our in-house Studio productions on top-performing topics.
Endpoints Studio offers a competitive opportunity to receive detailed insights about who is viewing and engaging with our news reports and our sponsored campaigns.
Reach a steadily growing, highly engaged audience that trusts Endpoints News as the most essential source of industry news and analysis.
Our Studio team uses first-party data and expertise to guide clients with creative and promotion best practices that optimize results across our advertising products and event productions.
Don’t just take it from us. Here’s a sampling of what our partners have had to say about running a campaign across the Endpoints network.
"We continue to advertise with Endpoints because they have an engaged, dedicated, and growing biotech readership. This readership is so critical to get in front of for generating awareness for new companies entering the biotech space. Our ads have continuously delivered high impressions and valuable leads – critical to our mission of establishing ourselves as a large player in the industry."
"We’ve already had an email asking for a meeting based on our ad in the Early Edition report – just getting a single project conversion would make it a good ROI for us!"
"We were so very pleased with this piece and grateful to the Endpoints team for the diligent Studio FSP write-up that so tactfully communicates our complex science. Thank you for the thoughtful article and we hope to partner with you again in the future!"
"We also just looked at our website traffic, which increased by 1000% during the Endpoints News week. Naturally, we are super happy with the collaboration and results. In fact, we have generated a number of very interesting leads already."
"We continue to advertise with Endpoints because they have an engaged, dedicated, and growing biotech readership. This readership is so critical to get in front of for generating awareness for new companies entering the biotech space. Our ads have continuously delivered high impressions and valuable leads – critical to our mission of establishing ourselves as a large player in the industry."
"We were thrilled to see this result from our webinar broadcast! A fantastic new record and bar set now. Thanks to the Endpoints Studio team for your help in making this such a success!"
"We're very pleased with the performance of this [FSP] placement – in part achieved by your team’s recommendations in the development process to optimise our headlines. I also appreciate the detail provided delving into performance of each native link and the benchmarks against your average metrics."
"We’ve already had an email asking for a meeting based on our ad in the Early Edition report – just getting a single project conversion would make it a good ROI for us!"
"We were so very pleased with this piece and grateful to the Endpoints team for the diligent Studio FSP write-up that so tactfully communicates our complex science. Thank you for the thoughtful article and we hope to partner with you again in the future!"